Sepsis, a systemic inflammatory response syndrome, remains a potentially lethal condition. (S)-1-α-Naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD712) is noted as a drug candidate for sepsis. Many studies have demonstrated its significant anti-inflammatory effects. Here we first examined whether CKD712 inhibits lipopolysaccharide (LPS)-induced arachidonic acid (AA) release in the RAW 264.7 mouse monocyte cell line, and subsequently, its inhibitory mechanisms. CKD712 reversed LPS-associated morphological changes in the RAW 264.7 cells, and inhibited LPS-induced release of AA in a concentrationdependent manner. The inhibition was apparently due to the diminished expression of a cytosolic form of phospholipase A 2 (cPLA 2 ) by CKD712, resulting from reduced NF-κB activation. Furthermore, CKD712 inhibited the activation of ERK1/2 and SAP/JNK, but not of p38 MAPK. CKD712 had no effect on the activity or phosphorylation of cPLA 2 and on calcium influx. Our results collectively suggest that CKD712 inhibits LPS-induced AA release through the inhibition of a MAPKs/NF-κB pathway leading to reduced cPLA 2 expression in RAW 264.7 cells.
INTRODUCTION
Sepsis (Septicemia, blood poisoning) represents a whole-body inflammatory state that is usually caused by infection with gram-negative bacteria (Levy et al., 2003) . Endotoxins from gram-negative bacteria like Escherichia coli that are released into the blood stream cause decreased tissue perfusion and oxygen delivery, multiple organ failure (septic shock), and death (Kumar Vinay, 2007) . Sepsis is also known as a systemic inflammatory response syndrome (SIRS), and remains a major challenge in medicine (Baron et al., 2006) . CKD712, (S)-1-α-naphthylmethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, is a newly synthesized tetrahydroisoquinoline alkaloid and an (S) enantiomer. It was originally extracted from Aconitum (known as Monkshood), and initially used as a cardio tonic, and has long been considered as a very important drug. It has also been used as a heart stimulant and diuretic in oriental herbal medicine (Zhou and Du, 2003) . Kang et al. (1999) reported that the (S)-form, which has shown more potent anti-inflammatory effects than the (R)-form or racemic mixture, significantly inhibited inducible nitric oxide synthase (iN-OS) expression, with concomitant decrease in nitric oxide (NO) production, by blocking the activation of nuclear factor-κB (NF-κB), leading to increased survival rates in a lipopolysaccharide (LPS)-treated murine model of sepsis (Park et al., 2006; 2011) .
A cytosolic form of phospholipase A 2 (cPLA 2 ) hydrolyzes phospholipids to arachidonic acid (AA) and lysophospholipids; this is the rate-limiting step during pro-inflammatory eicosanoid production (Clark et al., 1995; Leslie, 1997) . There are several pathways for AA production through the activation and translocation to cell membrane of cPLA 2 ; by increases in a) intracellular Ca 2+ levels (Glover et al., 1995) , b) direct activation by ceramide-1-phosphate (Lamour et al., 2009 ), c) phosphorylation by mitogen-activated protein kinase (MAPK) (Lin et al., 1993) , and d) transcriptional expression (Clark et al., 1995) . Recent evidence shows that cPLA 2 could be an essential effector in the pathogenesis of the septic shock (Kim et al., 2006; Levy et al., 2000; Roshak et al., 1994) and acute lung injury caused by the sepsis syndrome (Nagase et al., 2000; 2003) . Moreover, cPLA 2 , and not the secretory form of PLA 2 (sPLA 2 ), plays an important role in LPS-induced prostaglandin E 2 (PGE 2 ) formation in human monocytes (Roshak et al., 1994) . The disruption of a gene encoding cPLA 2, and subsequent treatment with a potent inhibitor of cPLA 2 , such as arachidonyl trifluoromethyl ketone, significantly attenuated LPS-induced acute lung injury in mice (Kim et al., 2006; Nagase et al., 2000; 2003) . These studies suggest that the pharmacological inhibition of cPLA 2 could be a novel therapeutic approach to sepsis.
In the present study, we have demonstrated the inhibitory effect of CKD712 on LPS-induced AA release and PGE 2 production. These effects may be due to inhibition of cPLA 2 expression, through the activation of a MAPK/NF-κB pathway.
MATERIALS AND METHODS

Materials
LPS (from E. coli, serotype O128:B12), protease inhibitor cocktail, phenylmethylsulfonyl fluoride (PMSF), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltrazolium bromide], and dithiothreitol (DTT) were purchased from Sigma Chemical Co. (USA). Arachidonyl trifluoromethyl ketone (AACOCF 3 ), SP600125, PD98059, and SB203580 were obtained from Biomol (Plymouth Meeting, USA). Anti-cPLA 2 , anti-COX-2, and anti-GAPDH antibodies were purchased from Santa Cruz Biotechnology (USA). Anti-MAPK antibodies (p42/44, p38 MAPK, and JNK) and anti-phospho-MAPK (p-p42/44, p-p38 MAPK, and p-JNK) antibodies were purchased from Cell Signaling technology ® (USA). 1-Stearoyl-2-(1- Cell culture RAW 264.7 cells were obtained from ATCC (USA). The growth medium consisted of DMEM (USA) supplemented with 10% fetal bovine serum (Gibco) and 1× antibiotics (penicillin and streptomycin; Gibco). The cultures were maintained in an incubator at 37°C, in an atmosphere containing 5% CO 2 .
Assay for arachidonic acid release
Sub-confluent cells in 6-well plates were labeled for 24 h with [ 3 H] arachidonic acid (0.5 μCi/ml) in DMEM containing 10% FBS and antibiotics. After labeling, the medium was removed, and the cells were washed 3 times with serum-free DMEM, followed by 30 min of incubation in this medium. After incubation, the indicated concentrations of CKD712 were added, and the cells were incubated for 1 h. Next, 1 μg/ml LPS was added, and arachidonic acid release was measured at the indicated times. To measure stimulated arachidonic acid release, an aliquot of medium was removed and centrifuged. The radioactivity in 100 μl of the supernatant was measured in a liquid scintillation counter (Tri-Carb 2910TR/Perkin Elmer LAS). The radioactivity of released arachidonic acid was normalized to the total radioactivity of the monolayer extracted with 1% Triton X-100.
Preparation of RAW 264.7-derived cPLA 2 RAW 264.7 cells were grown in 150 × 20-mm petri dishes and washed twice with TBS. The cells were harvested in homogenizing buffer containing 0.12 M NaCl, 1 mM EDTA, and 75 mM Tris-HCl, pH 9.0. The cell suspension was sonicated on ice 6 times for 3 s, with 5 s-intervals between each pulse to maintain ice-cold condition. The sonicated cells were centrifuged at 2,000 × g for 10 min at 4°C. The supernatant (lysates) was centrifuged at 100,000 × g for 1 h at 4°C. The supernatants (cytosolic fraction) were used as a source of cytosolic PLA 2 . For direct binding studies, cPLA 2 was partially purified from the cytosolic fraction of RAW 264.7 cells. Cells were grown in T175 flasks, and the cytosolic fractions were prepared by centrifugation at 100,000 × g after sonication in 125 mM NaCl, 25 mM Tris, and 1 mM EDTA, pH 9.0 (buffer H). The prepared sample was applied to a HiTrap™ Heparin HP column (1 ml, GE Healthcare) that was pre-equilibrated with buffer H at a flow rate of 0.5 ml/min. Because enzyme activity was recovered in the unbound fraction, unbound path-through (PT) protein was eluted with 5 ml of buffer H and diluted with equal volumes of 1 mM EDTA, and 50 mM Tris-HCl, pH 7.5 (buffer A). The diluted PT fraction was applied to MonoQ™ column (GE Healthcare) pre-equilibrated with buffer A at a flow rate of 1 ml/min. Unbound protein was eluted and rinsed with 25 ml of buffer A. The portion containing active enzyme was eluted at a flow rate of 1 ml/min using a 20-ml linear gradient of buffer A containing 1 M NaCl. An aliquot (20 μl) of each fraction (1 ml) was assayed for cPLA 2 activity. The fraction exhibiting the highest activity was used for testing the direct effects of CKD712 on cPLA 2 .
Assay of PLA 2 activity PLA 2 activity was assayed using the supernatant and pellet after centrifugation at 100,000 × g. Briefly, the standard incubation system (100 μl) for assaying PLA 2 activity contained PLA 2 preparations, 100 mM Tris-HCl, pH 7.4, 5 mM CaCl 2 and 4.5 nmol of substrate 2-[1- Immunoblotting RAW 264.7 cells were plated in 150 × 20-mm petri dishes at a density of ~2 × 10 6 cells per plate. After 24 h, the media were replaced with serum-free DMEM for 30 min, and the cells were incubated with indicated concentrations of CKD712 for 1 h, and then stimulated with 1 μg/ml LPS for 8 h. Treated cells were washed twice with TBS and collected in homogenizing buffer (75 mM Tris-HCl, 12 mM NaCl, 1 mM EDTA, pH 9.0, 20 μM pepstatin, 10 mM mercaptoethanol, 20 μM leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride). Cells were homogenized in a sonicator and centrifuged at 2,000 × g for 10 min to remove debris. Cell lysates were then centrifuged at 100,000 × g for 1 h, and the pellet was resuspended in homogenizing buffer. The protein concentrations of the supernatants and pellets were measured using Bradford's reagent (Biorad). Proteins were
